NewAmsterdam Pharma Company NV

Research NewAmsterdam Pharma Company NV (NAMS) on Bullrun: market cap USD 3.96B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerNAMS
• ExchangeNASDAQ
• CountryNetherlands
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 3.96B
• Financial periodFY2025
• RevenueUSD 22.50M
• Revenue growth-50.6%
• Net income-USD 203.00M
• Free cash flow-USD 148.03M

Valuation Snapshot

latest market cap is USD 3.96B.

About NewAmsterdam Pharma Company NV

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease.

Frequently asked questions

What is NewAmsterdam Pharma Company NV's market cap?

NewAmsterdam Pharma Company NV's market capitalization is USD 3.96B.

What does NewAmsterdam Pharma Company NV do?

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.